Key Developments: Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

30 Jan 2015
Change (% chg)

€0.24 (+0.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Fresenius SE & Co KGaA confirms FY 2014 outlook
Tuesday, 4 Nov 2014 01:00am EST 

Fresenius SE & Co KGaA:Confirms its FY 2014 outlook for sales to grow by a currency-adjusted 14 to 16 pct.Continues to expect FY 2014 adjusted net income to grow by 2 to 5 pct at constant currencies.  Full Article

Fresenius SE & Co KGaA raises FY 2014 sales outlook; confirms FY 2014 net income guidance
Wednesday, 30 Jul 2014 08:00pm EDT 

Fresenius SE & Co KGaA:Raises its FY 2014 sales outlook following acquisitions at Fresenius Medical Care, and expects sales to increase by 14 pct to 16 pct in constant currency.Says previously, it expected sales growth of 12 pct to 15 pct.Confirms fully FY 2014 net income guidance, and continues to expect increase of 2 pct to 5 pct in constant currency.  Full Article

Fresenius SE & Co KGaA subsidiary Fresenius Kabi enters into joint venture with Sistema JSFC and Zenitco Finance Management LLC
Thursday, 24 Apr 2014 08:00pm EDT 

Fresenius SE & Co KGaA:Says Fresenius Kabi enters into joint venture with Sistema JSFC, holding company in Russia, and Zenitco Finance Management LLC.Joint venture combines Fresenius Kabi’s Russian and CIS business with CJSC Binnopharm, subsidiary of Sistema, with minority stake owned by Zenitco.Fresenius Kabi to hold 51 pct stake in new company.Binnopharm is Russian manufacturer and distributor of I.V. drugs, infusion solutions and active pharmaceutical ingredients.Transaction expected to close by year-end 2014.  Full Article

Fresenius SE & Co KGaA to issue 375 million euros convertible bond - Reuters
Tuesday, 18 Mar 2014 02:40am EDT 

Fresenius SE & Co KGaA:Announces issuance of equity-neutral convertible bonds - Reuters.To issue 375 million euros equity-neutral convertible bonds due 2019.  Full Article

Fresenius SE & Co KGaA issues FY 2014 outlook and proposes FY 2013 dividend
Tuesday, 25 Feb 2014 01:00am EST 

Fresenius SE & Co KGaA:Projects sales growth of 12 pct to 15 pct in constant currency for FY 2014.FY 2013 sales of 20,331 million euro.FY 2014 revenue of 23,100 million euro - Thomson Reuters I/B/E/S.Expects net income attributable to shareholders to increase in FY 2014 by 2 to 5 pct in constant currency.Will propose a dividend increase of 14 pct to 1.25 euro per share for FY 2013.FY 2012 dividend was of 1.10 euro per share.  Full Article

German Cartel Office grants merger control clearance to Rhoen Klinikum AG for transaction with Fresenius/HELIOS
Thursday, 20 Feb 2014 07:18am EST 

Rhoen Klinikum AG:Announces that the German Cartel Office, granted merger control clearance for the transaction with Fresenius/HELIOS without restrictions and conditions.The merger control clearance comprises 40 clinics, medical centers and related companies and thus the entire sold portfolio except for the clinics in Cuxhaven, Waltershausen-Friedrichroda und Boizenburg and two management companies for medical centers.The excepted companies were, in coordination with the Cartel Office, removed from the sold portfolio already prior to the merger control clearance.The cleared transaction will for the most part be closed until end of Feb. by payment of the purchase price and transfer of the shares.  Full Article

Fresenius SE & Co KGaA Acquires 43 Hospitals and Fifteen Outpatient Facilities from Rhoen-Klinikum AG
Thursday, 12 Sep 2013 08:52pm EDT 

Fresenius SE & Co KGaA announced that it has signed a binding agreement to purchase the majority of Rhoen-Klinikum AG's hospitals, acquiring 43 hospitals with a total of approximately 11,800 beds as well as fifteen outpatient facilities. The purchase price of EUR 3.07 billion will be entirely debt-financed. Under the transaction, Fresenius will not assume any financial debt of Rhoen-Klinikum AG.  Full Article

Fresenius SE & Co KGaA Raises FY 2013 Guidance
Tuesday, 30 Jul 2013 12:59am EDT 

Fresenius SE & Co KGaA announced that it raises its full fiscal year 2013 earnings guidance, and thus expects net income to increase by 11% to 14% in constant currency. Previously, Fresenius expected fiscal year 2013 net income growth of 7% to 12% in constant currency. The Company fully confirms its fiscal year 2013 sales guidance, with sales expected to increase by 7% to 10% in constant currency.  Full Article

China Probes Pricing At Drugmakers Including Fresenius SE & Co KGaA-Reuters
Thursday, 4 Jul 2013 07:31am EDT 

Reuters reported that China's top economic planning agency is investigating costs and prices charged by drugmakers, including units of GlaxoSmithKline and Merck & Co Inc, as foreign firms come under pressure from Beijing over possible price-fixing. The move follows a separate probe into instant milk powder, which has already led to price cuts. The National Development and Reform Commission (NDRC) is surveying production costs and prices charged at multiple foreign and Chinese drug companies, according to a July 2, 2013 statement from the commission. News of the investigation was reported earlier on Thursday by the official Securities Daily newspaper. The NDRC will examine 27 companies on cost issues and 33 for pricing. The investigation is being done to understand the cost and pricing situation within the companies, and to adjust drug prices in a timely manner, the agency said. In addition to GSK and Merck, other foreign companies being investigated over costs include Astellas Pharma Inc, Novartis AG's generics unit Sandoz, Boehringer Ingelheim, Baxter International Inc and Fresenius SE & Co KGaA. An investigation team from NDRC will visit the companies involved between July and October, the agency said.  Full Article

Fresenius SE & Co KGaA Comments on FY 2013 Sales Growth
Tuesday, 26 Feb 2013 01:07am EST 

Fresenius SE & Co KGaA announced that it expects group sales growth of 7% to 10% in the fiscal year 2013.  Full Article

Fresenius plans to raise dividend after hitting 2014 goals

FRANKFURT - German healthcare group Fresenius plans to raise its dividend for the 22nd year in a row after hitting its financial targets for 2014, its chief executive told the Euro am Sonntag newspaper.

Search Stocks